NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

May 15, 2023

Study Completion Date

November 15, 2023

Conditions

Diabetes Mellitus, Type 2NASH - Nonalcoholic SteatohepatitisNAFLD

Interventions

DRUG

Pioglitazone

Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.

DRUG

Empagliflozin

Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.

DRUG

Pioglitazone + Empagliflozin

Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).

Trial Locations (1)

74800

RECRUITING

Aga Khan University Hospital, Karachi